These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 25887787)

  • 1. 17 years of clinical experience with phosphodiesterase type 5 inhibitors: what do we have yet to learn?
    Verze P; Cai T; Palmieri A; Mirone V
    Eur Urol; 2015 Oct; 68(4):681-2. PubMed ID: 25887787
    [No Abstract]   [Full Text] [Related]  

  • 2. Re: Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Seftel A
    J Urol; 2013 Oct; 190(4):1340. PubMed ID: 24029345
    [No Abstract]   [Full Text] [Related]  

  • 3. Re: Erectile function, erection hardness and tolerability in men treated with sildenafil 100 mg vs. 50 mg for erectile dysfunction.
    Seftel AD
    J Urol; 2014 Apr; 191(4):1078. PubMed ID: 24703144
    [No Abstract]   [Full Text] [Related]  

  • 4. Re: JinQiu Yuan, RenJie Zhang, ZuYao Yang, et al. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis. Eur Urol 2013;63:902-12.
    Jiann BP
    Eur Urol; 2014 Mar; 65(3):e40. PubMed ID: 24183420
    [No Abstract]   [Full Text] [Related]  

  • 5. Newer phosphodiesterase inhibitors: comparison with established agents.
    McNamara ER; Donatucci CF
    Urol Clin North Am; 2011 May; 38(2):155-63. PubMed ID: 21621082
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Re: Efficacy of Once-Daily Administration of Udenafil for 24 Weeks on Erectile Dysfunction: Results from a Randomized Multicenter Placebo-Controlled Clinical Trial.
    Seftel AD
    J Urol; 2015 Aug; 194(2):495. PubMed ID: 26195408
    [No Abstract]   [Full Text] [Related]  

  • 7. A broad-spectrum approach to daily tadalafil: making the big picture even bigger.
    Verze P; Arcaniolo D; La Rocca R; Mirone V
    Eur Urol; 2014 Feb; 65(2):465-6. PubMed ID: 24563912
    [No Abstract]   [Full Text] [Related]  

  • 8. [Continuous use of PDE5 inhibitors in the treatment of erectile dysfunction: New insights and opportunities].
    Puigvert AM; Prieto R; García F
    Rev Int Androl; 2018; 16(1):28-33. PubMed ID: 30063020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of phosphodiesterase type 5 inhibitors on penile rigidity variables during a period with no sexual stimulation: a laboratory setting double-blind study.
    Gökçe A; Demirtas A; Halis F; Ekmekcioglu O
    BJU Int; 2011 Jan; 107(2):264-7. PubMed ID: 20438562
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimization of sexual function outcome after radical prostatectomy using phosphodiesterase type 5 inhibitors.
    Kaiho Y; Yamashita S; Arai Y
    Int J Urol; 2013 Mar; 20(3):285-9. PubMed ID: 23311962
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Erection rehabilitation after radical prostatectomy: definite purpose, indefinite strategy.
    Burnett AL
    Eur Urol; 2014 Mar; 65(3):597-8. PubMed ID: 24268502
    [No Abstract]   [Full Text] [Related]  

  • 12. Simplified Interpretation of the Erectile Function Domain of the International Index of Erectile Function.
    Cappelleri JC; Tseng LJ; Luo X; Stecher V; Lue TF
    J Sex Med; 2016 Apr; 13(4):690-6. PubMed ID: 26936074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Re: Efficacy and safety of mirodenafil for patients with erectile dysfunction: a meta-analysis of three multicenter, randomized, double-blind, placebo-controlled clinical trials.
    Li J; Shi Q; Wei Q; Han P
    Aging Male; 2015 Jun; 18(2):71. PubMed ID: 25162329
    [No Abstract]   [Full Text] [Related]  

  • 14. [Vardenafil (levitra): new aspects of clinical efficacy].
    Gamidov SI; Iremashvili VV; Pavlovichev AA; Tazhetdinov OKh
    Urologiia; 2010; (6):44-7. PubMed ID: 21427994
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphodiesterase 5 inhibitors for the treatment of erectile dysfunction: a trade-off network meta-analysis.
    Chen L; Staubli SE; Schneider MP; Kessels AG; Ivic S; Bachmann LM; Kessler TM
    Eur Urol; 2015 Oct; 68(4):674-80. PubMed ID: 25817916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vardenafil improves penile erection in type 2 diabetes mellitus patients with erectile dysfunction: role of tropomyosin.
    Zamorano-León JJ; Olivier C; de Las Heras N; Mateos-Cáceres PJ; Brime Menéndez R; Rodríguez-Sierra P; Martín Palacios N; Manso LS; Modrego J; Segura A; Macaya C; López-Farré AJ
    J Sex Med; 2013 Dec; 10(12):3110-20. PubMed ID: 24112450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of Baseline Total Testosterone Level on Successful Treatment of Sexual Dysfunction in Men Taking Once-Daily Tadalafil 5 mg for Lower Urinary Tract Symptoms and Benign Prostatic Hyperplasia: An Integrated Analysis of Three Randomized Controlled Trials.
    Mulhall JP; Brock GB; Glina S; Baygani S; Donatucci CF; Maggi M
    J Sex Med; 2016 May; 13(5):843-51. PubMed ID: 27017071
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness and safety of oral phosphodiesterase type 5 inhibitors for erectile dysfunction: a systematic review and network meta-analysis.
    Yuan J; Zhang R; Yang Z; Lee J; Liu Y; Tian J; Qin X; Ren Z; Ding H; Chen Q; Mao C; Tang J
    Eur Urol; 2013 May; 63(5):902-12. PubMed ID: 23395275
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ED drugs after cancer treatment don't protect erectile function.
    Harv Mens Health Watch; 2014 Jul; 18(12):8. PubMed ID: 25219008
    [No Abstract]   [Full Text] [Related]  

  • 20. A state of art review on vardenafil in men with erectile dysfunction and associated underlying diseases.
    Chung E; Broc GB
    Expert Opin Pharmacother; 2011 Jun; 12(8):1341-1348. PubMed ID: 21548725
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.